IMELDA_2A: IMELDA, figure 2A

IMELDA_2AR Documentation

IMELDA, figure 2A

Description

Kaplan-Meier digitized data from IMELDA, figure 2A (PMID 25273343). A reported sample size of 284 for a primary endpoint of PFS in breast cancer.

Usage

IMELDA_2A

Format

A data frame of 185 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (bevacizumab, bevacizumab_capecitabine)

Source

Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1351–60.

Examples

summary(IMELDA_2A)

kmplot(IMELDA_2A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.